Tempus expands multi-year collaboration with Gilead for oncology research
Go back to Tempus expands multi-year collaboration with Gilead for oncology research| Gilead Sciences (NASDAQ: GILD) | Delayed: 149.92 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $149.92 | 52 Week High | $108.63 | |||
| Open | $149.92 | 52 Week Low | $71.39 | |||
| Day High | $149.92 | P/E | 82.83 | |||
| Day Low | $149.92 | EPS | $1.81 | |||
| Volume | 2,441 | |||||
| StemCells, Inc. (NASDAQ: TEM) | Delayed: 62.27 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $62.27 | 52 Week High | $0.45 | |||
| Open | $62.27 | 52 Week Low | $0.37 | |||
| Day High | $62.27 | P/E | N/A | |||
| Day Low | $62.27 | EPS | $-0.31 | |||
| Volume | 94,028 | |||||
